Novartis Ag (NVS) EV to EBITDA (2009 - 2026)
Novartis Ag (NVS) EV to EBITDA (2009 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EV to EBITDA |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
8.71 Mn |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
30.10 |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
13.43 |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
25.62 |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
-52.99 |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
16.72 |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
14.70 |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
-7.64 |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
14.50 |
| 10 |
Novartis Ag |
109.78 Bn |
109.09 Bn |
- |
6.37 |
| Date | Value |
|---|
| Mar 30, 2026 |
6.53 Mn |
| Mar 27, 2026 |
6.43 Mn |
| Mar 26, 2026 |
6.50 Mn |
| Mar 25, 2026 |
6.54 Mn |
| Mar 24, 2026 |
6.45 Mn |
| Mar 23, 2026 |
6.43 Mn |
| Mar 20, 2026 |
6.34 Mn |
| Mar 19, 2026 |
6.43 Mn |
| Mar 18, 2026 |
6.50 Mn |
| Mar 17, 2026 |
6.72 Mn |
| Mar 16, 2026 |
6.72 Mn |
| Mar 13, 2026 |
6.66 Mn |
| Mar 12, 2026 |
6.70 Mn |
| Mar 11, 2026 |
6.76 Mn |
| Mar 10, 2026 |
7.02 Mn |
| Mar 9, 2026 |
7.07 Mn |
| Mar 6, 2026 |
6.95 Mn |
| Mar 5, 2026 |
6.99 Mn |
| Mar 4, 2026 |
7.17 Mn |
| Mar 3, 2026 |
7.13 Mn |
